tetano
Editor, Senior Moderator
Expert Rev Clin Immunol. 2019 Jul 11. doi: 10.1080/1744666X.2019.1642748. [Epub ahead of print]
[h=1]Neonatal vaccine effectiveness and the role of adjuvants.[/h] Sakala IG[SUP]1,[/SUP][SUP]2[/SUP], Eichinger KM[SUP]3[/SUP], Petrovsky N[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Introduction: Neonates are less responsive to vaccines than adults, making it harder to protect newborns against infection. Neonatal differences in antigen presenting cell, B and T cell function, all likely contribute. A key question is whether novel adjuvants might be able to make neonatal vaccines more effective. Areas Covered: This review addresses the issues of how to improve neonatal vaccines, which we have defined as vaccines given in the first 4 weeks of life in a human infant or the first week of life in a mouse. A search was performed using keywords including 'neonatal immunity', 'neonatal immunisation', 'vaccine' and 'adjuvant' of PubMed articles published between 1960 and 2018. Expert Opinion: Sugar-like structures have recently been shown to prime the infant adaptive immune system to respond to vaccines, being potentially more effective than traditional adjuvants. Sugar-based compounds with beneficial adjuvant effects in neonatal vaccine models include delta inulin (Advax), curdlan, and trehalose 6,6'-dibehenate. Such compounds make interesting neonatal adjuvant candidates, either used alone or in combination with traditional innate immune adjuvants.
[h=4]KEYWORDS:[/h] Advax; Neonate; adjuvant; carbohydrate; delta inulin; immunity; influenza; vaccine
PMID: 31293189 DOI: 10.1080/1744666X.2019.1642748
[h=1]Neonatal vaccine effectiveness and the role of adjuvants.[/h] Sakala IG[SUP]1,[/SUP][SUP]2[/SUP], Eichinger KM[SUP]3[/SUP], Petrovsky N[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Introduction: Neonates are less responsive to vaccines than adults, making it harder to protect newborns against infection. Neonatal differences in antigen presenting cell, B and T cell function, all likely contribute. A key question is whether novel adjuvants might be able to make neonatal vaccines more effective. Areas Covered: This review addresses the issues of how to improve neonatal vaccines, which we have defined as vaccines given in the first 4 weeks of life in a human infant or the first week of life in a mouse. A search was performed using keywords including 'neonatal immunity', 'neonatal immunisation', 'vaccine' and 'adjuvant' of PubMed articles published between 1960 and 2018. Expert Opinion: Sugar-like structures have recently been shown to prime the infant adaptive immune system to respond to vaccines, being potentially more effective than traditional adjuvants. Sugar-based compounds with beneficial adjuvant effects in neonatal vaccine models include delta inulin (Advax), curdlan, and trehalose 6,6'-dibehenate. Such compounds make interesting neonatal adjuvant candidates, either used alone or in combination with traditional innate immune adjuvants.
[h=4]KEYWORDS:[/h] Advax; Neonate; adjuvant; carbohydrate; delta inulin; immunity; influenza; vaccine
PMID: 31293189 DOI: 10.1080/1744666X.2019.1642748